FDA Approves Truseltiq (infigratinib) for the Treatment of Cholangiocarcinoma

PALO ALTO, Calif. and LUGANO, Switzerland, May 28, 2021 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), through its affiliate QED Therapeutics, Inc., and Helsinn Group today announced that the US Food and Drug Administration (FDA) has...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news

Related Links:

Conditions:   Liver Malignant Tumors;   Cholangiocarcinoma Metastatic;   Pancreatic Cancer;   Melanoma Intervention:   Device: high dose rate brachytherapy Sponsor:   M.D. Anderson Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSION: Circulating miRNAs in bile-derived exosomes provide new information for the development of miRNA analysis in CCA. These miRNAs may represent the oncogenic characteristics of CCA tissue, enabling them to be used instead of tissue samples for the diagnosis of CCA. Further research investigating circulating miRNAs in bile exosomes may lead to more rational, targeted approaches to treatment.PMID:34549037 | PMC:PMC8424434 | DOI:10.4174/astr.2021.101.3.140
Source: Annals of Surgical Treatment and Research - Category: Surgery Authors: Source Type: research
Background: Cholangiocarcinoma (CCA) encompasses a heterogeneous group of malignant tumors with dismal prognosis and increasing incidence worldwide. Both late diagnosis due to the lack of early symptoms and the refractory nature of these tumors seriously compromise patients ’ welfare and outcomes.Summary: During the last decade, immunotherapy and, more specifically, modulation of immune checkpoints-mediated signaling pathways have been under the spotlight in the field of oncology, emerging as a potential therapeutic approach for the treatment of several cancers, including CCA. Generally, high expression levels of imm...
Source: Liver Cancer - Category: Cancer & Oncology Source Type: research
Cancer Gene Therapy, Published online: 21 September 2021; doi:10.1038/s41417-021-00387-5The LIN28B/TGF-β/TGFBI feedback loop promotes cell migration and tumour initiation potential in cholangiocarcinoma
Source: Cancer Gene Therapy - Category: Cancer & Oncology Authors: Source Type: research
We report a case of Maffucci syndrome withIDH1 mutation complicated by intrahepatic cholangiocarcinoma. The patient was a 35-year-old woman who was diagnosed with Maffucci syndrome in childhood. She was referred to our department because of a large hepatic tumor. Serum carcinoembryonic antigen was 27.1 ng/mL upon laboratory examination. CT scanning showed a large low-density tumor (90 × 70 mm) in the right lobe of the liver, and MRI revealed a multilobulated and fibrous tumor, which was observed as high signal intensity on T2- and diffusion-weighted images and low signal intensity on T1-weighted images. Positron emis...
Source: Case Reports in Oncology - Category: Cancer & Oncology Source Type: research
Br J Surg. 2021 Sep 20:znab320. doi: 10.1093/bjs/znab320. Online ahead of print.NO ABSTRACTPMID:34542590 | DOI:10.1093/bjs/znab320
Source: The British Journal of Surgery - Category: Surgery Authors: Source Type: research
In conclusion, as both antibodies resulted in mirror-image staining, the involvement of G8-144 and MECA-79 in O-glycan synthesis could be considered as potential favorable and unfavorable biomarkers, respectively, for CCA prognosis.PMID:34539864 | PMC:PMC8436361 | DOI:10.3892/ol.2021.13021
Source: Oncology Letters - Category: Cancer & Oncology Authors: Source Type: research
This study aimed to assess the correlation of CCA with various combinations ofO.viverrini infection and DM among a high-risk population in northeastern Thailand. MethodologyThis study included participants from 20 provinces in northeastern Thailand who had been screened for CCA in the Cholangiocarcinoma Screening and Care Program (CASCAP) between 2013 and 2019. Histories ofO.viverrini infection and DM diagnosis were obtained using a health questionnaire. CCA screening used ultrasonography with a definitive diagnosis based on histopathology. Multilevel mixed-effects logistic regression was performed to quantify the associat...
Source: PLoS Neglected Tropical Diseases - Category: Tropical Medicine Authors: Source Type: research
Biliary tract cancers (BTCs) are rare neoplasms that are mostly reported in first-world countries, with an incidence in Europe of approximately 1 per 100,000 inhabitants. BTCs are categorized as intrahepatic (iCCA), perihilar (pCCA), or distal cholangiocarcinomas (dCCA), or gallbladder carcinomas. Gemcitabine-platinum doublet chemotherapy is the standard-of-care in the first-line for advanced BTCs, giving an 8-month median progression-free-survival (PFS), with median overall survival ranging from 6 to 12 months [1].
Source: Digestive and Liver Disease - Category: Gastroenterology Authors: Tags: Correspondence Source Type: research
ConclusionsA laparoscopic approach to the caudate lobe using a left intercostal port is a new and ideal technique providing effective manipulation.
Source: Journal of Gastrointestinal Surgery - Category: Surgery Source Type: research
More News: Bile Duct Cancer | Cholangiocarcinoma | Drugs & Pharmacology | Food and Drug Administration (FDA) | Pharmaceuticals | Switzerland Health